Date 8 August 2017 **Sydney, Australia**

NOXOPHARM POSTS CORPORATE PRESENTATION AHEAD OF CONFERENCE

- **Presentation at Singapore Investor Conference**
- **Review of first year of operation**

Sydney, 8 August 2017: Noxopharm provides its corporate presentation to be presented at the 2017 ASX Growth Series Conference hosted in Singapore jointly by SparkPlus and Maybank Singapore on 21st August.

For further information, please contact:

Investor & Corporate Enquiries:
Prue Kelly
M: 0459 022 445
info@noxopharm.com
www.noxopharm.com

Company Secretary:
David Franks
T: +61 2 9299 9690 E:
E: dfranks@fa.com.au

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney, Melbourne and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:
Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operations Office:
Suite 3 Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

NOXOPHARM

ASX: NOX

Corporate Presentation

August 2017

Objective 1

To bring to market **by 2022** a drug (NOX66) that:

- sensitises most forms of cancer to radiotherapy and chemotherapy
- delivers improved survival outcomes for most cancer patients
- becomes a standard-of-care drug in cancer therapy

Based on the ability of NOX66 …..

to increase the cancer cell-killing ability of

- standard cytotoxic chemotherapy drugs by >2000x
- radiotherapy by 10x

….. without affecting healthy cells.

Objective 2

To develop a pipeline of non-oncology drugs, capable of crossing into the brain, with first-in-class activity against a number of common community diseases/disorders of significant unmet

Based on the proprietary LIPROSE® drug delivery technology platform….

enabling certain classes of drugs to cross the blood-brain barrier

NOX66. Current status …..

- First-in-human study
  - Commenced April 2017 (Phase 1b/2a)
  - Late-stage solid cancers. Safety/efficacy in 16 patients/7 month treatment course
  - No safety issues to date: NOX66 alone or in combination therapy with chemotherapy (carboplatin)

- 5 other studies due to start before November 2017
  - 4x NOX66 + radiotherapy
  - 1x NOX66 + radiotherapy + chemotherapy

NOX66. Aim of current Phase 1/Phase 2 program…. to identify clinical indication for registration study

Potential indications:

- *Direct radio-sensitisation* → complete remission of irradiated lesions in metastatic, castrate-resistant prostate cancer or NSCLC receiving palliative radiotherapy for symptomatic relief
- *Abscopal response* → remission of non-irradiated tumours in metastatic, castrate-resistant prostate cancer or NSCLC receiving palliative radiotherapy for symptomatic relief
- *Chemo-sensitisation* → increased PFS of patients with a late-stage solid cancer (? NSCLC/SCLC) in combination with carboplatin

NOX66. Opportunity for significant disruption of standard practices in cancer therapy …

- **Improved response rates**
  Meaningful response rates to radiotherapy and chemotherapy in late-stage cancers currently unresponsive to any therapies
- **Allow palliative (less toxic) standard therapies**
  Sensitise cancer cells to radiotherapy and chemotherapy, allowing dosages too low to be considered normally. Facilitate treatment in patients currently considered too ill or frail to withstand standard dosages of treatment
- **Abscopal responses**
  In patients with multiple cancers, irradiate 1-2 lesions and achieve shrinkage of all tumours (irradiated + non-irradiated)

Anticipated reporting: first-in-human study

NOXOPHARM

Study NOX66.001

- Combination NOX66 + carboplatin
- Dose-escalation
  - NOX66: 400 mg and 800 mg
  - Carboplatin: AUC4 for 3 months followed by AUC6 for 3 months
- 16 patients in total (8 per NOX66 dose)
- 11 patients recruited 1/8/2017
- Full recruitment expected mid-Sept 2017
- Scans for tumor response (RECIST) at 3 and 6 months

Matrix of 4 end-points based on drug dosage and 3- and 6-month scans

400 mg/AUC4 mid-Oct 2017	400 mg/AUC6 mid-Jan 2018
800 mg/AUC4 mid-Dec 2017	800 mg/AUC6 mid-March 2018

Anticipated reporting: current clinical program



STUDY 2. Late-stage prostate cancer. Multiple secondaries. NOX66 + palliative radiotherapy maximum 2 lesions

STUDY 3. Late-stage solid cancer. Multiple secondaries. NOX66 + palliative radiotherapy maximum lesions

STUDY 4. Late-stage solid cancers. Multiple secondaries. NOX66 + palliative radiotherapy + standard chemotherapy

NOX66
Registration (Phase 3) study timetable



NOX66
Registration study considerations …..

- Radiotherapy studies relatively short: *2-3 weeks treatment; scans at 3 and 6 months; estimated duration = 24 months*
- Multi-national trial: *US, UK, EC, CIS, AUSTRALIA, HK*
- CRO and Data Manager appointed
- Aim to seek accelerated approval: *based on current trial data*
- Estimated cost = US$25M (based on estimated 300 patients)

Intellectual Property strategy …..

- **Global Patent Attorneys**
- **PCT patent application strategy; selected territories with > 90% of global anti-cancer drug sales**
- **Patent applications filed on LIPROSE ® technology/method of administration/use**
- **2nd generation products (different dosage forms) under development**
- **Ongoing R&D to extend IP coverage**

Manufacturing strategy …..

- API (idronoxil) to be manufactured by Indian CMO: *GMP scale-up under development*
- Final dosage form to be manufactured by Australian CMO: *dedicated pilot plant under development (Melbourne) for manufacture of clinical trials batches*
- NOXOPHARM to establish in-house facility for final dosage form *(providing greater security over IP, assurance of supply, value adding)*

Commercialisation strategy …..

- NOXOPHARM to undertake registration studies and regulatory submissions in major territories
- Out-licence for major territories (North America, EC, UK, Japan)
- Marketing partnerships in certain territories (China, Russia, CIS)
- In-house sales/marketing into selected Asia-Pacific territories

Execution strategy …..

- Exoperienced team in place to execute all key work streams
- Clinical development, medical affairs, regulatory affairs and manufacturing, all headed by experienced personnel with large pharma experience
- Medical Advisor (part-time) is high profile medical oncologist, previously Medical Director of large pharma company
- Other personnel (directors for business development, commercial activities, marketing etc) will be appointed as required

Board of directors ……..

Peter Marks BEc LLB MBA

Chairman of the Board

Non-Executive Director

Dr Graham Kelly BSc BVSc PhD

Managing Director & CEO

Executive Director

Dr Ian Dixon MBA, PhD

Non-Executive Director

Senior Management ……..



Key Messages

- WE EXPECT TO KNOW BY END OF 2017 OF THE SUCCESS OF OUR MISSION
- WE AIM TO BE IN A REGISTRATION STUDY BY END OF 2018
- WE AIM TO HAVE MARKETING APPROVAL BY 2022
- A SUCCESSFUL OUTCOME IS A MAJOR SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET
- REALISTIC POTENTIAL TO BECOME STANDARD OF CARE DRUG IN MOST CANCER PATIENTS

✓ Lean operation
✓ Experienced team

✓ A number ofkey inflection points anticipated within next 12 months

✓ Several potential blockbuster drugs candidates

Key metrics

Shares outstanding	**85M** : 38M free; 47M escrowed (July 2018)
Other	22.5M options ($0.30) (July 2018)
Market Cap (31.7.2017)	$33.4M
Cash position	AU$ 6.0M IPO (9 Aug 2016) AU$ 2.8M (Jun 2017)

Disclaimer

- *This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.*
- *This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.*
- *This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.*
- *Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.*
- *Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.*

NOXOPHARM

NOXOPHARM

Dr Graham Kelly
Chief Executive Officer

graham.kelly@noxopharm.com